Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Mezzion Pharma Co Ltd (140410)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
37,750 -950    -2.45%
30/04 - Closed. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7140410002 
  • Volume: 78,057
  • Bid/Ask: 37,750 / 37,800
  • Day's Range: 37,700 - 38,750
Mezzion Pharma 37,750 -950 -2.45%

Mezzion Pharma Co Ltd Company Profile

 
Get an in-depth profile of Mezzion Pharma Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

45

Equity Type

ORD

Mezzion Pharma Co.,Ltd. engages in the development, manufacturing, and sale of pharmaceutical products in South Korea. It is developing udenafil, a PDE5 protein for the treatment of erectile dysfunction, benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, and single heart failure diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

Contact Information

Address Seokcheon Building 7th floor
570 Samsung-ro Gangnam-gu Seoul, 06163
South Korea
Phone 82 2 560 8000
Fax 82 2 563 6517

Top Executives

Name Age Since Title
Won-Bae Kim 66 - Director
Dong-Hyun Park 68 - Chairman, CEO & President
Jefferson J. Gregory 68 2014 Director
Dong-Hoon Lee 67 - Independent Outside Director
Cheol-Shik Shin 70 - Independent Outside Director
Won-Am Cho 62 - Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

140410 Comments

Write your thoughts about Mezzion Pharma Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
sure ki
sure ki Feb 07, 2021 9:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.reddit.com/user/ChocopieK/comments/lez7ed/mezzionkosdaq_krx140410_recommended/
JongHyeon Han
JongHyeon Han Aug 18, 2019 2:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mezzion Pharma will be attending to AHA(American Heart Association) in November this year for their phase 3 trial results. . . . Strong BUY by Nomura, targeting the stock price, 190,000(KRW). . . Nomura will be setting up IR(Investor Relations) of Mezzion and other Korean prospective companies in New York, September 24,25. . . Mezzion's phase 3 trial is supported by NIH/PHN which probably give you the signal that the trial will be successful.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email